Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $42 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential Highlighted
- Strong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits
- Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth
- Strong Financial Position and Promising Cardiovascular Developments Propel NewAmsterdam Pharma’s Growth Potential
- NewAmsterdam Pharma Reports Q1 2025 Financial Results